MedTrace Logo

Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout

NCT01519687 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-01-27

No results posted yet for this study

Summary

The purpose of this study is to determine whether levotofisopam is safe and effective in the treatment of hyperuricemia and gout.

Conditions

  • Hyperuricemia
  • Gout

Interventions

DRUG

levotofisopam

50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7

Sponsors & Collaborators

  • Pharmos

    lead INDUSTRY

Principal Investigators

  • John S. Sundy, MD, PhD · Duke Clinical Research Unit

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01519687 on ClinicalTrials.gov